The high rates of attrition that occur in drug development are widely regarded as problematic, but the failure of well-designed studies benefits both researchers and healthcare systems by, for example, generating evidence about disease theories and demonstrating the limits of proven drugs. A wider recognition of these benefits will help the biomedical research enterprise to take full advantage of all the information generated during the drug development process.
London, A. J., & Kimmelman, J. (2015). Why clinical translation cannot succeed without failure. ELife, 4(NOVEMBER2015), 1–5. https://doi.org/10.7554/eLife.12844